Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPFZ.L Regulatory News (PFZ)

  • There is currently no data for PFZ

Form 38.5b

4 Nov 2015 13:13

RNS Number : 5543E
Goldman Sachs & Co.
04 November 2015
Β 

Ap27

Β 

Β 

FORMΒ 38.5(b)

Β 

IRISHΒ TAKEOVERΒ PANEL

Β 

DISCLOSUREΒ UNDERΒ RULEΒ 38.5(b)Β OFΒ THEΒ IRISHΒ TAKEOVERΒ PANEL ACT,Β 1997,Β TAKEOVERΒ RULES,Β 2013

Β 

DEALINGSΒ BYΒ CONNECTEDΒ EXEMPTΒ PRINCIPALΒ TRADERSΒ WITHOUTΒ RECOGNISEDΒ INTERMEDIARYΒ STATUS,Β ORΒ WITHΒ RECOGNISEDΒ INTERMEDIARYΒ STATUSΒ BUTΒ NOTΒ DEALINGΒ INΒ AΒ CLIENT-SERVINGΒ CAPACITY

Β 

Β 

1. KEYΒ INFORMATION

Β 

Name of exempt principal trader

(GS) GOLDMAN, SACHS & CO.

Company dealt in

PFIZER INC

Class of relevant security to which the dealings being disclosed relate (Note 1)

USD ordinary

Date of dealing

03 November 2015

Β 

2. INTERESTS AND SHORT POSITIONS

Β 

(a) InterestsΒ andΒ shortΒ positionsΒ (followingΒ dealing)Β inΒ theΒ classΒ ofΒ relevantΒ securityΒ dealtΒ inΒ (NoteΒ 2)

Β 

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

321,342 (0.00)

6,453,475 (0.10)

(2) Derivatives (other than options)

0 (0.00)

Β 0 (0.00)

(3) Options and agreements to purchase/sell

0 (0.00)

Β 0 (0.00)

Total

321,342 (0.00)

6,453,475 (0.10)

Β 

(b) InterestsΒ andΒ shortΒ positionsΒ inΒ relevantΒ securitiesΒ ofΒ theΒ company,Β otherΒ thanΒ theΒ classΒ dealtΒ inΒ (NoteΒ 2)

Β 

Class of relevant security:

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

(2) Derivatives (other than options)

(3) Options and agreements to purchase/sell

Total

Ap28

Β 

Β 

3. DEALINGSΒ (NoteΒ 3)

Β 

(a) PurchasesΒ andΒ sales

Β 

Purchase/sale

Number of relevant securities

Price per unit (Note 4)

Sale (Loan New)

519,857

N/A

Purchase (Loan Full Return)

519,857

N/A

Sale (Loan New)

844,882

N/A

Purchase (Loan Full Return)

844,882

N/A

Purchase (Loan Partial Return)

819,956

N/A

Purchase (Loan Full Return)

1,032,348

N/A

Sale (Loan New)

6,407,576

N/A

Sale (Loan New)

543,649

N/A

Purchase (Loan Full Return)

543,649

N/A

Sale (Loan New)

543,649

N/A

Purchase (Loan Full Return)

543,649

N/A

Sale (Loan New)

332,709

N/A

Purchase (Loan Full Return)

332,709

N/A

Sale (Loan New)

543,649

N/A

Purchase (Loan Full Return)

543,649

N/A

Purchase (Loan Full Return)

173,160

N/A

Sale (Loan New)

543,649

N/A

Purchase (Loan Full Return)

543,649

N/A

Sale (Borrow Partial Return)

301,233

N/A

Sale (Loan New)

543,649

N/A

Purchase (Loan Full Return)

543,649

N/A

Sale (Loan New)

350,733

N/A

Purchase (Loan Partial Return)

253,900

N/A

Purchase (Loan Partial Return)

51,600

N/A

Purchase (Loan Full Return)

45,233

N/A

Sale (Loan New)

415,886

N/A

Purchase (Loan Full Return)

415,886

N/A

Sale (Loan New)

543,649

N/A

Purchase (Loan Full Return)

543,649

N/A

Sale (Loan Adjust)

20,148

N/A

Sale (Loan Adjust)

14,249

N/A

Sale (Loan Adjust)

10,343

N/A

Sale (Loan Adjust)

6,618

N/A

Purchase (Loan Partial Return)

377

N/A

Purchase (Loan Partial Return)

3,149

N/A

Purchase (Loan Partial Return)

266

N/A

Purchase (Loan Partial Return)

2,227

N/A

Purchase (Loan Partial Return)

193

N/A

Purchase (Loan Partial Return)

1,617

N/A

Purchase (Loan Partial Return)

124

N/A

Purchase (Loan Partial Return)

1,034

N/A

(b) DerivativesΒ transactionsΒ (otherΒ thanΒ optionsΒ transactions)

Β 

Product name,

e.g. CFD

Nature of transaction

(Note 5)

Number of relevant securities

(Note 6)

Price per unit

(Note 4)

Β 

Β 

(c) OptionsΒ transactionsΒ inΒ respectΒ ofΒ existingΒ relevantΒ securities

Β 

Β 

(i) Writing,Β selling,Β purchasingΒ orΒ varying

Β 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 4)

Β 

Β 

(ii) Exercising

Β 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 4)

Β 

Β 

(d) OtherΒ dealingsΒ (includingΒ transactionsΒ inΒ respectΒ ofΒ newΒ securities)Β (NoteΒ 3)

Β 

Nature of transaction

(Note 7)

Details

Price per unit

(if applicable) (Note 4)

Β 

Β 

Ap29

Β 

OTHERΒ INFORMATION

Β 

Agreements,Β arrangementsΒ orΒ understandingsΒ relatingΒ toΒ optionsΒ orΒ derivatives

Β 

FullΒ detailsΒ ofΒ anyΒ agreement,Β arrangementΒ orΒ understandingΒ betweenΒ theΒ person disclosingΒ andΒ anyΒ otherΒ personΒ relatingΒ toΒ theΒ votingΒ rightsΒ ofΒ anyΒ relevantΒ securitiesΒ 

underΒ anyΒ optionΒ referredΒ toΒ onΒ thisΒ formΒ orΒ relatingΒ toΒ theΒ votingΒ rightsΒ orΒ futureΒ 

acquisitionΒ orΒ disposalΒ ofΒ anyΒ relevantΒ securitiesΒ toΒ whichΒ anyΒ derivative referredΒ toΒ onΒ thisΒ formΒ isΒ referenced.Β IfΒ none,Β thisΒ shouldΒ beΒ stated.

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

IsΒ aΒ SupplementalΒ FormΒ 38.5(b)Β attached?Β (NoteΒ 8) Β YES/NO

Β 

Β 

Date of disclosure

04 November 2015

Contact name

Aadithya Rao and Yiannis Bardis

Telephone number

+44(20) 7051 9046 / +44(20) 7774 7107

Name of offeree/offeror with which connected

Pfizer Inc

Nature of connection (Note 9)

Advisor to Offeror

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
ISEEADFLEFFSFFF
Date   Source Headline
12th May 201411:55 amRNSForm 8.3 - Pfizer, Inc.
12th May 201411:54 amRNSForm 8.5 (EPT/RI) - Pfizer Inc
12th May 201411:39 amRNSForm 8 (DD) - Pfizer Inc.
12th May 201411:38 amRNSRule 2.10 Announcement
12th May 201411:34 amRNSForm 8.5 (EPT/RI) - Pfizer Inc
12th May 201411:33 amRNSForm 8 (DD) - [Pfizer Inc]
12th May 201411:31 amRNSForm 8.5 (EPT/RI) - Pfizer Inc
12th May 201411:31 amRNSForm 8 (DD) - [Pfizer Inc]
12th May 201411:30 amRNSForm 8.5 (EPT/RI)
12th May 201411:26 amRNSForm 8.5 (EPT/RI) - Pfizer Inc
12th May 201411:00 amRNSRule 2.10 Announcement
12th May 201410:53 amRNSForm 8.3 - Pfizer Inc
12th May 201410:52 amRNSForm 8.3 - AstraZeneca Plc
12th May 201410:17 amRNSStatement from Pfizer Inc.
12th May 20147:00 amRNSTHE BENEFITS OF A POTENTIAL COMBINATION
12th May 20147:00 amPRNForm 8.3 - Pfizer Inc.
9th May 20146:23 pmRNSForm 8.3 - Pfizer Inc - Amendment
9th May 20146:20 pmRNSForm 8.3 - Pfizer Inc
9th May 20146:10 pmRNSForm 8.5 (EPT/NON-RI) Amendment
9th May 20146:08 pmRNSForm 8.5 (EPT/NON-RI) Amendment
9th May 20146:06 pmRNSForm 8.5 (EPT/RI) Pfizer INC
9th May 20144:45 pmRNSForm 8 (DD) - [Pfizer Inc] - Amendment
9th May 20144:33 pmRNSForm 8 (DD) - [Pfizer Inc]
9th May 20143:38 pmRNSForm 8.3 - Pfizer Inc
9th May 20143:37 pmBUSForm 8.3 - Pfizer Inc - Amendment
9th May 20143:33 pmRNSForm 8.5 (EPT/RI) - Pfizer Inc
9th May 20143:30 pmRNSForm 8.3 - Pfizer Inc.
9th May 20143:22 pmRNSForm 8.3 - Pfizer Inc.
9th May 20143:11 pmRNSForm 8.3 - Pfizer INC
9th May 20143:10 pmRNSForm 8.3 - Astrazeneca PLC
9th May 20142:33 pmBUSForm 8.3 - Pfizer Inc.
9th May 20142:28 pmBUSForm 8.3 - Pfizer Inc
9th May 20142:28 pmBUSForm 8.3 - Pfizer Inc
9th May 20142:24 pmRNSForm 8.5 (EPT/RI) Replacement Pfizer Inc
9th May 20142:22 pmRNSForm 8.3 - [PFIZER INC]
9th May 20142:15 pmRNSForm 8.5 (EPT/RI) Pfizer Inc
9th May 20142:12 pmRNSForm 8.3 - [PFIZER INC]
9th May 20141:58 pmRNSForm 8.5 (EPT/RI) Replacement Pfizer Inc
9th May 20141:57 pmBUSForm 8.3 - Pfizer Inc.
9th May 20141:56 pmRNSForm 8.5 (EPT/RI) - Amendment
9th May 20141:50 pmRNSForm 8 (DD) - Pfizer Inc.
9th May 20141:44 pmRNSForm 8.5 (EPT/NON-RI) Replacement - Pfizer INC
9th May 20141:41 pmRNSForm 8.3 - Pfizer Inc
9th May 20141:09 pmRNSForm 8.3 - AstraZeneca Plc
9th May 20141:08 pmRNSForm 8.3 - Pfizer
9th May 201412:35 pmRNSForm 8.3 - Pfizer Inc
9th May 201412:24 pmRNSForm 8.5 (EPT/NON-RI)
9th May 201412:21 pmRNSForm 8.5 (EPT/RI)
9th May 201412:19 pmRNSForm 8.3 - AstraZeneca Plc
9th May 201412:12 pmRNSForm 8.3 - Pfizer Inc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.